<--- Back to Details
First PageDocument Content
Biology / Partial thromboplastin time / Thromboplastin / Coagulation / Lupus anticoagulant / Von Willebrand disease / Anticoagulant / Medical device / Plasma / Coagulation system / Medicine / Blood tests
Date: 2011-08-29 00:29:49
Biology
Partial thromboplastin time
Thromboplastin
Coagulation
Lupus anticoagulant
Von Willebrand disease
Anticoagulant
Medical device
Plasma
Coagulation system
Medicine
Blood tests

510K SUMMARY-820 ASSAY ONLY TEMPLATE Kitox37

Add to Reading List

Source URL: www.accessdata.fda.gov

Download Document from Source Website

File Size: 220,43 KB

Share Document on Facebook

Similar Documents

Center Information: Subcenter: Inland Northwest Blood Center Inland Northwest Blood Center 210 W. Cataldo Ave.

Center Information: Subcenter: Inland Northwest Blood Center Inland Northwest Blood Center 210 W. Cataldo Ave.

DocID: 1riKA - View Document

Microsoft Wordfile00

Microsoft Wordfile00

DocID: 1r9dZ - View Document

News Releases  Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

News Releases Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

DocID: 1qHpD - View Document

RECOTHROM, Thrombin topical (Recombinant) Package Insert

RECOTHROM, Thrombin topical (Recombinant) Package Insert

DocID: 1qv5K - View Document

Quester leads £3.1million investment in Haemostatix 23 January 2006 – Quester, a leading UK venture capital company, announced today that it has led a £3.1million investment in Haemostatix Ltd, a drug design and deve

Quester leads £3.1million investment in Haemostatix 23 January 2006 – Quester, a leading UK venture capital company, announced today that it has led a £3.1million investment in Haemostatix Ltd, a drug design and deve

DocID: 1qk7W - View Document